[EN] SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS [FR] TRIAZINONES SUBSTITUÉES EN TANT QU'AGONISTES DU RÉCEPTEUR DE L'HORMONE THYROÏDIENNE
The present invention provides dihydrooxydiazinone compounds of general formula (I) : in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
The present invention provides compounds of formula I:
which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
[EN] CYCLIC INHIBITORS OF HEPATITIS B VIRUS<br/>[FR] INHIBITEURS CYCLIQUES DU VIRUS DE L'HÉPATITE B
申请人:OSPEDALE SAN RAFFAELE SRL
公开号:WO2020016434A1
公开(公告)日:2020-01-23
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.
[EN] PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE DICARBOXAMIDE UTILISÉS COMME INHIBITEURS DE BROMODOMAINE
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD
公开号:WO2017202742A1
公开(公告)日:2017-11-30
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
本发明涉及式(I)的化合物及其盐,含有这种化合物的药物组合物以及它们在治疗中的应用。
TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
申请人:Incyte Corporation
公开号:US20150175604A1
公开(公告)日:2015-06-25
The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.